X
|
STUDENT DIGITAL NEWSLETTER ALAGAPPA INSTITUTIONS |
|
Robert T. Eberhardt, MD
In selecting measures for this article erectile dysfunction following radical prostatectomy buy cheap super cialis 80 mg, we supplemented the physical disability measures reviewed elsewhere with those that span a cross-section of tasks xarelto erectile dysfunction cheap super cialis 80 mg on-line, activities 498a impotence super cialis 80 mg line, and roles that make up daily life erectile dysfunction drugs online 80 mg super cialis with amex. However stress and erectile dysfunction causes super cialis 80 mg on line, they allow arthritis researchers to collect data on physical disability erectile dysfunction herbal remedies cheap super cialis 80 mg with amex, its determinants, and outcomes that are useful for comparing within and across diseases and health conditions. We include these latter measures in our review as examples of easy-to-administer questions that are being applied to a wide range of diseases and health states. These measures reflect examples of efforts researchers have made to expand physical disability beyond tasks and activities to include limitations in roles like socializing with others, employment, care of others, leisure, and hobbies. No one measure reviewed in this article is likely to satisfy the needs of all researchers wanting to measure physical disability. Some measures will be too narrowly focused either in their emphasis on arthritis or in the domains they capture. Others may provide a broad overview or snapshot of disability, but lack detail that would be sufficient for clinicians in making decisions for patients. The latter time frame results in respondents trying to characterize their disability in terms of what is usual or normal for them. Despite this, the different measures of physical disability capture the impact of arthritis on a broad range of activities and roles that are meaningful to people living with the disease. They are useful in descriptive or surveillance studies identifying areas of need and they have the potential to generate information on the societal impact or burden of disease. All of the measures would benefit from S309 additional testing to examine their predictive validity and responsiveness to change. The interest and importance of measuring a broad range of activities and roles affected by health conditions like arthritis means that we will likely continue to see refinements, greater sophistication, and greater standardization of measures. Traditionally, measures have been developed with little or no input from other cultures and then simply translated into other languages. This has sometimes resulted in poorer validity when the measure is applied to diverse samples. Item banks and computerized adaptive testing are also being applied to measures of disability to maximize the information gained from measures while minimizing time and costs of measurement administration. Researchers also are eager to test measures across different diseases for the purposes of comparative studies, to adapt measures to assess the personal and economic cost of disease, and to use physical disability measures for evaluating treatments and interventions. As such, we can anticipate continued improvements in the quality and application of physical disability measures over time. Other domains not described in detail here are symptoms (pain), role (work), social interaction (social activity, family support), and affect (tension, mood). The 28 items capture 6 domains: mobility S310 (5 items); walking and bending (5 items); hand and finger function (5 items); arm function (5 items); self-care tasks (4 items); and household tasks (4 items). Physical function subscales measure trouble (or absence of trouble) with mobility, walking and bending, hand and finger function, and arm function and are assessed on a 5-point Likert-type scale with 1 all days, 2 most days, 3 some days, 4 few days, and 5 no days. Subscales measuring self-care and household tasks are assessed with 1 always, 2 very often, 3 sometimes, 4 almost never, and 5 never. Original scale items were developed to go beyond disease activity and to measure a broader array of components identified as important to health by the World Health Organization. However, floor and ceiling effects have been observed depending on the patient group observed (26,27). If an item is missing, the average score of the other scale items may be substituted prior to calculation of subscores. No cut off values or normative values are available but scale scores may be adjusted to account for comorbidities. However, many studies discuss the measure using 5 dimensions: physical function, symptom, affect, social interaction, and role. It is a lengthy questionnaire, but not burdensome in terms of reading level required or emotional content. Scoring by hand completed in approximately 10 minutes; computerized scoring can be completed in seconds. Available in English, French, Dutch, Swedish, Chinese, Norwegian, Italian, German, Japanese, Spanish, Greek, Hebrew, Portuguese, Turkish, Russian, and Persian. The factor structure identified by the scale developers has not been examined as part of validity testing. However, principal components factor analyses excluded the role items and reported on a slightly different 5-factor solution than the core domains. There are 26 items, including upperextremity functioning (8 items, 2 overlap with lowerextremity functioning), lower-extremity functioning (5 items), affect (4 items), symptoms (3 items), social interaction (4 items), and role (2 items). Response options depend on the item and are either 1 (all days), 2 (most days), 3 (some days), 4 (few days), and 5 (no days), or 1 (always), 2 (very often), 3 (sometimes), 4 (almost never), and 5 (never). The questions are not burdensome in terms of the reading level required or their emotional content. Scoring by hand takes approximately 10 minutes; computerized scoring can be completed in seconds. The measure asks about physical functioning, pain, psychological status, and social interactions. Patients and experts reached S312 consensus on items critical to the scale concepts and used information from item analysis as a guide. In general, missing data are not reported as a problem with the exception of the role subscale. Depending on the joints affected, some floor and ceiling effects have been found, especially in the physical function subscales. Little attention is given to disability with instrumental activities or social roles. It is not clear whether the mea- Gignac et al sure was not sensitive to change or whether the intervention did not result in meaningful change. Other measures of work disability and role participation provide more in-depth information on this aspect of disability. However, more research is needed to determine its usefulness as a measure to guide clinical decision making at point of contact with patients. It was developed in 1981 to facilitate international comparisons of disability and monitor changes in disability over time across a range of health conditions. Responses are on a 4-level scale: yes (without difficulty), yes (with minor difficulty), yes (with major difficulty), and no (not able to do). Although a substantial percentage (50%) of interviews used proxy respondents, further analyses determined that inconsistencies were not due to proxy respondents ([50] as cited in [49]). However, there may be wording variations and the items are not used as a single measure. Floor effects are not uncommon in those under 65 years of age, with many people reporting no difficulty with any of the activities. The measure was developed by the European Quality of Life Group (EuroQol) to act as a core set of items for use in international studies measuring health-related quality of life across a wide range of health conditions and treatments. It provides a simple descriptive profile and single index values of health status. A constant is also subtracted if one or more dimensions are scored at 2 or 3, and a further constant if one or more dimensions are scored at 3. Weights have been derived for over 14 countries, with additional weights in development. Where possible, researchers should use the algorithms specific to their country by consulting the EuroQol web site. The EuroQol web site must be consulted to register studies and to determine the appropriate rates for a country. In terms of cost, whether licensing fees exists is determined by the EuroQol Executive Office and is based on information provided by users. For example, a score of 11222 would indicate no difficulties with mobility and self care, but some/moderate problems with usual activities, pain/discomfort, and anxiety/depression. Although originally created by EuroQol beginning in 1987, membership has grown to include members from North America, Asia, Africa, Australia, and New Zealand. The goal of the measure was to create an easy-to-administer core set of items for use in international studies across a wide range of health conditions and treatments. The dimensions were selected after a Disability detailed examination of existing health status measures, including the Quality of Well-Being Scale, Sickness Impact Profile, Nottingham Health Profile, and Rosser Index. The number of health states in each dimension was deliberately kept to a minimum so that the measure could easily be administered and used for decision making. Floor effects are not unusual in general populations, with individuals reporting 11111. Among patients with ankylosing spondylitis, floor effects in the 5 dimensions ranged from 10. Comparing telephone and face-to-face interviews in a sample of older adults, McPhail and colleagues found moderate to high levels of agreement. This may also be responsible for the ceiling and floor effects noted in a number of studies. Specif- S315 ically, the patient acceptable symptom state cut point with 80% specificity was estimated to be 0. Minimal clinically important improvement cut points assessed by 80% specificity varied from 0. Some authors have argued that there are important dimensions missing and a bimodal distribution of scores may compromise the validity of the measure and its ability to detect change. However, the measure is not detailed enough to use as a clinical decision making tool. May be useful as core variable to describe populations, but does not provide a lot of detail. It can be used for community health studies, population surveillance, or clinical assessments. Seven additional items in the life activities and participation domains are asked of individuals reporting any difficulties with activities. These items ask about the number of days health problems resulted in missing, reducing time with, or slowing down activities and roles. Questions are assessed on a 5-point Likert-type scale, where 1 none, 2 mild, 3 moderate, 4 severe, and 5 extreme or cannot do. It has been administered in population and community health surveillance studies, as part of clinical assessments, and in intervention research. Gignac et al respondents, and the interviewer-administered version can aid participants with literacy and other difficulties completing the questionnaire. The questionnaire is not burdensome in terms of reading level required or emotional content. If respondents indicate any difficulties, they are asked up to 24 additional questions according to the interviewer guide. Languages available include Albanian, Arabic, Bengali, Chinese (Mandarin), Croatian, Czech, Danish, Dutch, English, Finnish, French, German, Greek, Hindi, Italian, Japanese, Kannada, Korean, Norwegian, Portuguese, Romanian, Russian, Serbian, Slovenian, Spanish, Sinhala, Swedish, Tamil, Thai, Turkish, and Yoruba. Written and verbal prompts are provided to help Psychometric Information Method of development. Development included a 19-country cross-cultural sample for psychometric analysis and screening. Field testing occurred in 2 waves and included members of the general population in good health, people with physical disorders/conditions, people with mental or emotional disorders, and people with problems related to alcohol or drug use (104,105). However, questions related to employment, school, and sexual activities have higher amounts of missing data or refusal rates. Data for arthritis has often been combined with those of other diseases and not presented separately. For example, domain and total scores have significantly correlated with clinical disease features. Research examining responsiveness and sensitivity to change in samples with arthritis is lacking. Similar effect sizes were found in a 3-week spa intervention with individuals with ankylosing spondylitis (103). It can be used across a wide range of health levels and conditions and has been applied to samples of middle-aged and even younger adults. Physical disablement is measured with questions about personal maintenance; mobility and travel; exchange of information; social, community, and civic activities; home life; paid or volunteer work; and involvement in economic activities. These are divided into 2 components: function (difficulty with basic tasks involving lower-extremity function [e. Eight additional questions are asked of individuals who use a cane, walker, or other walking device, bringing the total to 72 questions. Within the function subscale, there are questions assessing upper-extremity function (7 items), basic lower-extremity function (14 items), and advanced lowerextremity function (11 items). For each activity/role, respondents are asked to indicate how frequently they perform the activity and to what extent they feel limited in their performance. Frequency questions assess social roles (9 items) and personal roles (7 items), and limitation questions assess instrumental roles (12 items) and management roles (4 items). Function questions ask about difficulty with tasks and are measured on a 5-point Likerttype scale, where 1 cannot do, 2 quite a lot, 3 some, 4 a little, and 5 none. Activities are also responded to in terms of "to what extent do you feel limited in.
Tumors may extend through the liver capsule to adjacent organs (adrenal latest news erectile dysfunction treatment purchase 80mg super cialis otc, diaphragm kidney disease erectile dysfunction treatment 80mg super cialis overnight delivery, and colon) or may rupture erectile dysfunction mental discount super cialis 80 mg without a prescription, causing acute hemorrhage and peritoneal metastasis erectile dysfunction treatment penile prosthesis surgery discount 80 mg super cialis with amex. The classification considers the presence or absence of vascular invasion (as assessed radiographically or pathologically) erectile dysfunction exam what to expect buy super cialis 80 mg amex, the number of tumor nodules (single versus multiple) impotence drugs over counter generic 80 mg super cialis with mastercard, and the size of the largest tumor (5 cm vs. For pathologic classification, vascular invasion includes gross as well as microscopic involvement of vessels. Major vascular invasion is defined as invasion of the branches of the main portal vein (right or left portal vein; this does not include sectoral or segmental branches) or as invasion of one or more of the three hepatic veins (right, middle, or left). Multiple tumors include satellitosis, multifocal tumors, and intrahepatic metastases. Invasion of adjacent organs other than the gallbladder or with perforation of the visceral peritoneum is considered T4. Validation of T1, T2, and T3 categories of this staging system is based on multivariate analyses of outcome and survival data of single-institution and multi-institution studies of hepatic resection of hepatocellular carcinoma worldwide. The survival curves obtained from analysis of the database of the International Cooperative Study Group for Hepatocellular Carcinoma are presented in Figures 18. The system has been independently validated in several large cohorts of patients who underwent hepatic resection for hepatocellular worldwide. Recently, this system was validated in a large cohort of patients who underwent liver transplantation (Figure 18. As such, this is the first staging system independently validated in patients following both hepatic resection and liver transplantation. Clinical staging depends on imaging procedures designed to demonstrate the size of the primary tumor and vascular invasion. Surgical exploration is not carried out if imaging shows that complete resection is not possible or if the hepatic reserve is deemed insufficient for safe resection. When advanced underlying liver disease (cirrhosis) dominates the prognosis, primary tumor factors (T classification) may become less relevant in terms of prognosis. Complete pathologic staging consists of evaluation of the primary tumor, including histologic grade, regional lymph node status, and underlying liver disease. Survival of patients with T1 tumors (solitary tumor without vascular invasion), stratified by size. Liver 193 In order to view this proof accurately, the Overprint Preview Option must be set to Always in Acrobat Professional or Adobe Reader. Job Name: - /381449t Regional lymph node involvement is rare (5%) except in the fibrolamellar variant of hepatocellular carcinoma. The grade is based on the cytopathologic study of nuclear pleomorphism as described by Edmonson and Steiner. Because of the prognostic significance of underlying liver disease in hepatocellular carcinoma, it is recommended that the results of the histopathologic analysis of the adjacent (non-tumorous) liver be reported. Although grade and underlying liver disease have prognostic significance, they are not included in the current staging system. For patients who undergo tumor resection, the main predictor of poor outcome is a positive surgical margin (grossly or microscopically involved tumors indicative of incomplete resection). Other prognostic factors associated with decreased survival include major vessel invasion and tumor size >5 cm in patients with multiple tumors. Job Name: - /381449t Hepatocellular carcinoma is by far the more common of the two types of primary carcinoma of the liver. The staging classification does not apply to primary sarcomas or metastatic tumors, and no longer applies to tumors of the bile ducts (cholangiocarcinomas including mixed hepatocholangiocarcinoma), which are now considered in a separate, new staging system (see Chap. The histologic type and subtype should be recorded, since they may provide prognostic information. Underlying liver disease but not tumor factors predict long-term survival after hepatic resection of hepatocellular carcinoma. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Histopathologic evaluation of hepatocellular carcinoma with special reference to small early stage tumor. Pathological aspects of hepatocellular carcinoma: a critical review of prognostic factors. Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Prognostic value and clinical relevance of the 6th edition 2002 American Joint Committee on Cancer staging system in patients with resectable hepatocellular carcinoma. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Tumor size predicts vascular invasion and histologic grade: implications for expanding the criteria for hepatic transplantation. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Prognostic evaluation of the new American Joint Committee on Cancer/ International Union Against Cancer staging system for hepatocellular carcinoma: analysis of 112 cirrhotic patients resected for hepatocellular carcinoma. Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgical resection of primary hepatocellular carcinoma extending to adjacent organ(s). Factors affecting long-term outcome after hepatic resection for hepatocellular carcinoma. Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. The "y" categorization is not an estimate of tumor prior to multimodality therapy. Hepatocellular carcinoma, tumors of the perihilar bile duct, and gallbladder carcinomas are classified separately. The tumors of the bile ducts can be anatomically subdivided into three categories including intrahepatic, perihilar, and distal cholangiocarcinoma. The proportion of cholangiocarcinoma that is accounted for by intrahepatic tumors is approximately 20%. Clinically, these intrahepatic tumors can be difficult to differentiate from metastatic adenocarcinomas from other primary sites. The etiologic factors that predispose to the development of intrahepatic cholangiocarcinoma include primary sclerosing cholangitis, hepatobiliary parasitosis, intrahepatic lithiasis, and chronic viral hepatitis. The incidence of intrahepatic cholangiocarcinoma is age-dependent, with a progressive increase in cases starting in the sixth decade of life and peaking in the ninth decade. Although less common than either hepatocellular carcinoma or hilar bile duct Intrahepatic Bile Ducts 201 In order to view this proof accurately, the Overprint Preview Option must be set to Always in Acrobat Professional or Adobe Reader. Job Name: - /381449t cancer, the incidence of intrahepatic cholangiocarcinoma is increasing. The development of a separate staging structure for intrahepatic cholangiocarcinoma, independent of hepatocellular carcinoma, is warranted based on several differences in clinical features. Unlike hepatocellular carcinoma, multiple analyses have determined that for intrahepatic cholangiocarcinoma tumor size is not a significant prognostic factor. Additionally, intrahepatic cholangiocarcinoma differs from hepatocellular carcinoma because it has a variety of distinct growth patterns including a mass forming type, a periductal infiltrative type, and combinations of these two types. Although it can be difficult to determine the extent of local disease on radiographic imaging, the major prognostic factors included in the staging system (tumor number, vascular invasion, perforation of the visceral peritoneum, and regional lymph node involvement) are often available from either high-resolution cross-sectional imaging/cholangiography or surgical exploration. In contrast, the periductal infiltrating type of cholangiocarcinoma demonstrates a diffuse longitudinal growth pattern along the bile duct. The percentage of patients with the purely mass forming type is estimated to be 60% of all patients with intrahepatic cholangiocarcinoma, while the purely periductal infiltrating type represents 20% of all cases and a mixed pattern of mass forming and periductal infiltrating type represents the remaining 20% of cases of intrahepatic cholangiocarcinoma. Limited analyses suggest that the diffuse periductal infiltrating type is associated with a poor prognosis. However, comparison of the prognostic significance of this variable to other prognostic factors is lacking. Either histologic type may invade vascular structures, although this is less commonly observed for mass forming intrahepatic cholangiocarcinoma. Anatomically, the intrahepatic bile ducts extend from the periphery of the liver to the second order bile duct ducts (see perihilar bile duct definition). At the hilar plate, the right and left hepatic bile ducts enter the liver parenchyma (Figure 19. Histologically these bile ducts are lined by a single layer of tall uniform columnar cells. The walls of the bile ducts have a layer of subepithelial connective tissue and muscle fiber. However, these muscle fibers are typically sparse or absent within the hepatic parenchyma. There is a periductal neural component, which is frequently involved by cholangiocarcinomas. The tumor growth patterns of intrahepatic cholangiocarcinoma include the mass forming type, the periductal infiltrating type, and a mixed type. Mass forming intrahepatic cholangiocarcinoma shows a radial growth pattern invading into the adjacent liver parenchyma with well-demarcated gross margins. Compared with primary hepatocellular carcinoma, regional lymph node metastases are more commonly associated with intrahepatic cholangiocarcinoma. The lymph node drainage patterns from the intrahepatic bile ducts demonstrate laterality. For intrahepatic cholangiocarcinomas, disease spread to the celiac and/or periaortic and caval lymph nodes are considered distant metastases (M1). Intrahepatic cholangiocarcinomas usually metastasize to other intrahepatic locations (classified in the T category as multiple tumors) and to the peritoneum, and subsequently, to the lungs and pleura (classified in the M category as distant metastasis). The T classification of invasive intrahepatic cholangiocarcinoma is determined by the number of tumors present (solitary vs. Liver diagram differentiating intrahepatic bile ducts (open lumens) from extrahepatic bile ducts (across lumens) and mass forming tumor growth pattern (A) from periductal infiltrating growth pattern (B). The definition of the term "multiple tumors" includes satellitosis, multifocal tumors, and intrahepatic metastasis. Vascular invasion includes both major vessel invasion [defined as invasion of the branches of the main portal vein (right or left portal vein) or as invasion of one or more of the three hepatic veins (right, middle, or left)] and microscopic invasion of smaller intraparenchymal vascular structures identified on histopathologic examination. Direct invasion of adjacent organs, including colon, duodenum, stomach, common bile duct, portal lymph nodes, abdominal wall, and diaphragm is considered T3 disease, not as distant metastasis. Extraregional nodal involvement and other distant metastatic sites are classified as M1 disease. For patients treated with surgical resection, the main predictors of poor outcome include regional lymph node involvement and incomplete resection. Other important prognostic factors include the finding of satellitosis or multiple intrahepatic tumors, vascular invasion, and periductal infiltrating tumor growth pattern. Validation of T1, T2, T3, and N1 categories is based on multivariate analyses of outcome and survival data of single institution and multi-institution studies of patients with intrahepatic cholangiocarcinoma. Clinical staging depends on imaging procedures designed to demonstrate the tumor growth pattern of intrahepatic cholangiocarcinoma, the number of intrahepatic masses, and the presence or absence of vascular invasion. Surgical exploration is carried out if imaging shows that a complete resection is possible and that hepatic reserve is sufficient for a safe resection. Radiographic assessment for the presence or absence of distant metastases prior to surgical exploration is warranted. Complete pathologic staging consists of evaluation of the primary tumor, including tumor number, involvement of local regional lymph nodes, and the presence or absence of vascular invasion. Solitary tumors with no vascular invasion and no lymph node involvement or metastasis are classified as T1. Tumors that perforate the visceral peritoneum, with or without invasion of extrahepatic structures are classified as T3. The pathologic definition of the periductal infiltrating type is the finding of a diffuse longitudinal growth pattern along the intrahepatic bile ducts on both gross and microscopic examination. T4 includes the diffuse periductal infiltrating tumors and the mixed mass forming and periductal infiltrating tumors. Stage I tumors are defined as T1 without regional lymph node metastasis (pN0, cN0). T1: Solitary tumor without vascular invasion; T2: Solitary tumor with vascular invasion or multiple tumors; T3: Tumor perforating the visceral peritoneum or involving the local extra hepatic structures by direct invasion. Intrahepatic Bile Ducts 203 In order to view this proof accurately, the Overprint Preview Option must be set to Always in Acrobat Professional or Adobe Reader. These include the following: Intrahepatic cholangiocarcinoma Mass forming tumor growth pattern Periductal infiltrating tumor growth pattern Mixed mass forming and periductal infiltrating growth pattern Mixed Hepatocellular this staging classification does not apply to primary sarcomas of the liver stroma or to liver metastases from other sites. The histopathologic subtype and, in the case of intrahepatic cholangiocarcinoma, the tumor growth pattern both should be recorded, since they may provide prognostic information. Surgical treatment of 32 patients with peripheral intrahepatic cholangiocarcinoma.
Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence erectile dysfunction pump rings cheap super cialis 80 mg with visa. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids erectile dysfunction herbal supplements buy super cialis 80 mg mastercard. Elevated serum B lymphocyte stimulator levels in patients with systemic immunebased rheumatic diseases online doctor erectile dysfunction order super cialis 80mg without a prescription. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus erectile dysfunction 5-htp buy super cialis 80 mg amex. Clinical pharmacokinetics and pharmacodynamics of biologic therapeutics for treatment of systemic lupus erythematosus erectile dysfunction doctor called super cialis 80 mg without a prescription. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-twoweek randomized erectile dysfunction meaning cheap super cialis 80 mg free shipping, double-blind, placebocontrolled study. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. Comparison of intravenous and subcutaneous exposure supporting dose selection of subcutaneous belimumab systemic lupus erythematosus Phase 3 program. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis. Urine protein-to-creatinine ratio in an untimed urine collection is a reliable measure of proteinuria in lupus nephritis. Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or 76 azathioprine/methylprednisolone. A double-blind controlled trial comparing cyclophosphamide, azathioprine and placebo in the treatment of lupus glomerulonephritis. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual. Prevalence of factors influencing cancer risk in women with lupus: social habits, reproductive issues, and obesity. Cancer risk in systemic lupus: an updated international multi-centre cohort study. Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: a meta-analysis of prospective cohort studies. Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta-analysis. Association of 77 smoking with cutaneous manifestations in systemic lupus erythematosus. Effect of autoimmune diseases on risk and survival in histology-specific lung cancer. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: A metaanalysis of the literature. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression? Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Smoking and the risk of systemic lupus erythematosus: an updated systematic review and cumulative metaanalysis. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year followup study. Ability of non-fasting and fasting triglycerides to predict coronary artery disease in lupus patients. Frequency of established cardiovascular disease and its risk factors in Chinese patients with systemic lupus erythematosus. Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythematosus. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids. Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-ofconcept cohort study. Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. Association of systemic lupus erythematosus with angiographically defined coronary artery disease: a retrospective cohort study. Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. Prevalence and risk factors for coronary artery calcification following kidney transplantation for systemic lupus erythematosus. Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. Premature atherosclerosis in pediatric systemic lupus erythematosus: risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Chronic kidney disease and the risks of death, cardiovascular events, and 80 hospitalization. Treatment of active lupus nephritis with voclosporin: Rapid remission over 48 weeks. Gonadal failure with cyclophosphamide therapy for lupus nephritis: advances in fertility preservation. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases. Prevalence and correlation of conventional and lupus-specific risk factors for cardiovascular disease in Chinese systemic lupus erythematosus patients. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. Pulse corticosteroid therapy for refractory thrombocytopenia in systemic lupus erythematosus. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Successful treatment of refractory thrombocytopenia with mycophenolate mofetil in a patient with systemic lupus erythematosus. Evaluation of azathioprine in autoimmune thrombocytopenia and lupus erythematosus. Prolonged immunoglobulin and platelet infusion for treatment of immune thrombocytopenia. Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia. Treatment of severe thrombocytopenia in systemic lupus erythematosus with intravenous gammaglobulin. A case of systemic lupus erythematosus expressing intractable thrombocytopenia remedied effectively by intermittent and continuous administrations of a small amount of immune globulin. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: the response to splenectomy. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus. Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares. Cyclophosphamide versus methylprednisolone for treating neuropsychiatric involvement in systemic lupus erythematosus. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients. Therapeutic plasma exchange for the management of refractory systemic autoimmune diseases: report of 31 cases and review of the literature. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome. New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Efficacy of mycophenolate mofetil in antimalarialresistant cutaneous lupus erythematosus. Mycophenolate mofetil and hydroxychloroquine: an effective treatment for recalcitrant cutaneous lupus erythematosus.
Syndromes
Scales set too low (0-20 mmHg) may result in clipping of all or part of the waveform impotence urologist buy super cialis 80mg with amex. Scales set too high (0-150 mmHg) may result in a "damped" appearance due to waveform compression erectile dysfunction aafp proven 80mg super cialis, leading to inappropriate troubleshooting or non-recognition catheter migration into a wedge position or into the right ventricle erectile dysfunction protocol reviews 80 mg super cialis with mastercard. The Swan-Ganz catheter is a flow-directed catheter and the tip will not usually flow to this lung region erectile dysfunction homeopathic drugs super cialis 80mg. Some blood flow occurs since the pulmonary arterial pressure is greater than the alveolar pressure erectile dysfunction at 17 cheap 80mg super cialis with amex. However erectile dysfunction treatment by yoga purchase super cialis 80 mg without prescription, the waveforms on inspiration will be negative due to the greater inspiratory decrease in intrathoracic pressure than the inspiratory increase in the cardiac volumes. The values recorded should be obtained at end-expiration when the intrathoracic pressure influence is minimal. End of expiration is identified as the beginning of inspiration where the intra-thoracic pressure starts to decrease. Swan and Ganz demonstrated reliability and reproducibility of the thermodilution method with a special temperature sensing pulmonary artery catheter. Since that time, the thermodilution method of obtaining cardiac output has become a standard for clinical practice. A known amount of solution with a known temperature is injected rapidly through the proximal lumen of the catheter. This cooler than blood temperature solution mixes with the surrounding blood, and the temperature is measured downstream in the pulmonary artery by a thermistor. The resultant change in temperature is then plotted on a time and temperature curve and is similar to the one produced by the indicator-dilution method. A modified Stewart-Hamilton equation is used to calculate the cardiac output taking into consideration the change in temperature as the indicator. This is followed by a smooth curve and slightly prolonged downslope back to the baseline. With high cardiac output, the cooler injectate is carried more quickly through the heart, and the temperature returns to baseline faster. Potential Errors in Cardiac Output Curves Temperature Uneven injecton technique Injection Uneven upstroke on curve Time Injection Severe artifact on both upstroke and downstroke of curve Injectate delivered in over 4 seconds B Temperature Temperature Time Prolonged injection time Injection Time B, Abnormal cardiac output curves that produce an erroneous cardiac output value. The platform may be used with the Edwards advanced hemodynamic monitoring portfolio including the ClearSight finger cuff, FloTrac sensor, Edwards oximetry central venous catheter and VolumeView set. The amount of history shown for monitored parameters can be configured by adjusting the time scale. Physiology screen: the physiology screen displays monitored parameters using a visual representation of the heart and circulatory system and their relevant measured volume. In addition, the value within the globe will flash when the parameter is alarming. Physio relationship screen: the physio relationship screen displays most of the parameters available on the system and their relationship to each other. The screen displays lines connecting the parameters highlighting the relationship of the parameters to each other. Furthermore, it can also be placed on a tabletop, pole or rack to meet individual patient requirements. HemoSphere advanced monitor screens Graphical trend: Allows clinicians to select, place, and track interventions over time while providing key parameter trending data. Graphical tabular: Useful for viewing both graphical and tabular format parameters on one screen. Cockpit: Combines larger, easy-to-read numbers with specific color target ranges, parameter and alarms to clearly indicate patient status and monitoring needs. Physio-relationship screen: Depicts the balance between oxygen delivery and consumption, allowing clinicians to identify the root cause of the imbalance and the most appropriate intervention. Real-time physiology screen: Depicts real-time changes occurring in patients by delivering visual and numeric parameters. It visually displays advanced parameters on the screen which are arranged by preload, contractility and afterload and which provide you potential insight into the cause of a hypotensive event. The lower the value, the lower the likelihood that a hypotensive event will occur. Decision support for treatment decisions should integrally provide information on all three aspects, since they often inter-relate. Clinical Decision Support Software dP/dt is best used in conjunction with stroke volume variation and stroke volume or cardiac output assessment. Eadyn is best used in conjunction with stroke volume variation (in ventilated patients) and stroke volume or cardiac output assessment. Giving volume to increase the preload and increase the stroke volume leads to an increase in cardiac output and arterial pressure; therefore, the afterload on the ventricle increases. Increasing afterload (increasing aortic pressure) by increasing systemic vascular resistance, will reduce the stroke volume. The resulting increased end-systolic volume, however, leads to a secondary increase in end-diastolic volume because more blood is left inside the ventricle following ejection and this extra blood is added to the venous return, thereby increasing ventricular filling, which increases contractility (Frank-Starling mechanism) and partially offsets the reduction in stroke volume caused by the initial increase in afterload. Edwards Clinical Education Quick Reference Note: the following algorithms and protocols are for educational reference only. It is up to each individual clinician and institution to select the treatment that is most appropriate. This protocol application is part of a patented treatment algorithm co-owned by the University of Pittsburgh and Michael R. Nexfin noninvasive continuous hemodynamic monitoring: Validation against continuous pulse contour and intermittent transpulmonary thermodilution derived cardiac output in critically ill patients. Validation of a new transpulmonary thermodilution system to assess global end-diastolic volume and extra-vascular lung water. Stroke volume variation as a predictor of fluid responsiveness in patients undergoing brain surgery. Abilities of pulse pressure variations and stroke volume variations to predict fluid responsiveness in prone position during scoliosis surgery. Case scenario: Respiratory variations in arterial pressure for guiding fluid management in mechanically ventilated patients. Noninvasive continuous cardiac output by the Nexfin before and after preload-modifying maneuvers. Use of pulse pressure variation and stroke volume variation in spontaneously breathing patients to assess dynamic arterial elastance and to predict arterial pressure response to fluid administration. Pulmonary artery false aneurysms secondary to Swan-Ganz pulmonary artery catheters. Outcome of intraoperative goal-directed therapy using Vigileo/FloTrac in high-risk patients scheduled for major abdominal surgeries: A prospective randomized trial. Dynamic arterial elastance as a predictor of arterial pressure response to fluid administration: A validation study. The rate-pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris. Principles of gas exchange: Diffusion of oxygen and carbon dioxide through the respiratory membrane. The microcirculation and lymphatic system: Capillary fluid exchange, interstitial fluid, and lymph fluid. Accuracy and trending ability of the fourth-generation Flotrac/Vigileo system in patients with low cardiac index. Pulse waveform hemodynamic monitoring devices: recent advances and the place in goaldirected therapy in cardiac surgical patients. Volumetric preload measurement by thermodilution: A comparison with transoesophageal echocardiography. Common pitfalls and tips and tricks to get the most out of your transpulmonary thermodilution device: results of a survey and state-of-the-art review. Facing acid-base disorders in the third millennium- the Stewart approach revisited. Hemodynamic monitoring in the critically ill: An overview of current cardiac output monitoring methods. Fluid responsiveness prediction using Vigileo/FloTrac measured cardiac output changes during passive leg raise test. The pulmonary physician in critical care 2: Oxygen delivery and consumption in the critically ill. Association of fluid resuscitation initiation within 30 minutes of severe sepsis and septic shock recognition with reduced mortality and length of stay. Stroke volume variation for prediction of fluid responsiveness in patients undergoing gastrointestinal surgery. Pulmonary artery occlusion pressure: Measurement, significance, and clinical uses. A simple physiologic algorithm for managing hemodynamics using stroke volume and stroke volume variation: Physiologic optimization program. Physiologic goaldirected therapy in the perioperative period: the volume prescription for high-risk patients. Bedside assessment of extravascular lung water by dilution methods: Temptations and pitfalls. Global end-diastolic volume as an indicator of cardiac preload in patients with septic shock. Dynamic arterial elastance to predict arterial pressure response to volume loading in preload-dependent patients. Arterial dP/dtmax accurately reflects left ventricular contractility during shock when adequate vascular filling is achieved. Usefulness of measures of SvO2, SpO2, vital signs, and derived dual oximetry parameters as indicators of arterial blood gas variables during weaning of cardiac surgery patients from mechanical ventilation. Defining the boundaries of bedside pulse contour analysis: dynamic arterial elastance. Calculating arterial pressure-based cardiac output using a novel measurement and analysis method. Continuous central venous and pulmonary artery oxygen saturation monitoring in the critically ill. Evaluation of a mathematical model to predict intrapulmonary shunt non-invasively. Use of transpulmonary thermodilution to measure extravascular lung water index in a ventilated patient. Systematic review of uncalibrated arterial pressure waveform analysis to determine cardiac output and stroke volume variation. Non-invasive radial pulse wave assessment for the evaluation of left ventricular systolic performance in heart failure. Noninvasive pulse pressure variation and stroke volume variation to predict fluid responsiveness at multiple thresholds: a prospective observational study. Comparison of continuous non-invasive finger arterial pressure monitoring with conventional intermittent automated arm arterial pressure measurement in patients under general anaesthesia. Distribution of blood flow in isolated lung; relation to vascular and alveolar pressures. What has resulted is an extensive line of hemodynamic monitoring tools including catheters, sensors and bedside patient monitors that continue to evolve hemodynamic monitoring in critical care medicine. Critical care clinicians around the world have used Edwards products to clinically manage more than 30 million patients. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events. All other trademarks are the property of their respective owners or its affiliates. Lundin Editors Renal Pharmacotherapy Dosage Adjustment of Medications Eliminated by the Kidneys 123 Renal Pharmacotherapy Larry K. Lundin Editors Renal Pharmacotherapy Dosage Adjustment of Medications Eliminated by the Kidneys Editors Larry K. Permissions for use may be obtained through RightsLink at the Copyright Clearance Center. The use of general descriptive names, registered names, trademarks, service marks, etc. While the advice and information in this book are believed to be true and accurate at the date of publication, neither the authors nor the editors nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein. Due to variably compromised ability to eliminate certain drugs from the body, patients with kidney disease often present with complex and potentially challenging clinical issues related to adjustment of drug dosages. These inconsistencies may lead to further confusion and additional potential errors. Available resources for adjustment of dosages of drugs in patients with renal insufficiency have been found to be broadly inconsistent and imprecise. A systematic review of dosage recommendations for 100 commonly prescribed medications listed in four widely used compendia found disparities in all of these resources in their recommendations for adjustments of dosage and dosage interval [8]. These differences ranged from minor disagreement regarding suggested dosage amount for a specific medication to divergence as broad and conflicting as no adjustment needed versus contraindicated.
Super cialis 80mg for sale. Natural Home Remedies To Cure Ed / Erectile Dysfunction With Apple Cider Vinegar.